April 17, 2013 / 6:36 PM / 4 years ago

FDA panel recommends approval of Glaxo/Theravance lung drug

April 17 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve an experimental treatment for smoking-related lung damage made by GlaxoSmithKline Plc and Theravance Inc .

The drug, Breo, is an inhaled treatment for chronic obstructive pulmonary disease (COPD), a condition that includes emphysema, chronic bronchitis or both. COPD is the third-leading cause of death in the United States, according to federal data.

Analysts were expecting a favorable review based on the FDA staff review, which was posted to the FDA’s website on Monday. (Reporting By Toni Clarke in Washington; Editing by Gerald E. McCormick)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below